Company / R&D per Share
BIOCRYST PHARMACEUTICALS INC R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.76
FY2025
5-year range
$0.76 / $1.36
FY2021-FY2025
Trend
-10.0%
vs FY2024
Sector context
#157 of 208
Health Care
What the data says
BIOCRYST PHARMACEUTICALS INC's r&d per share of $0.76 is lower than 75% of companies in the Health Care sector (FY2025). R&D per Share has declined for 3 consecutive years, from $1.36 in FY2022 to $0.76 in FY2025.
Based on SEC 10-K filings.
0.76 in FY2025 with a 5-year CAGR of +0.7%.
Declined from $1.13 to $0.76 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -17.7%
- 5-Year CAGR
- +0.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 208This company $0.76 Sector average $12.19
▼
-93.8% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 10.0% year-over-year.
- Ranks #157 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.76 | -10.0% |
| FY2024 | $0.84 | -25.0% |
| FY2023 | $1.13 | -17.3% |
| FY2022 | $1.36 | +16.9% |
| FY2021 | $1.17 | +58.6% |
| FY2020 | $0.74 | -20.6% |
| FY2019 | $0.93 | +12.6% |
| FY2018 | $0.82 | -9.4% |
| FY2017 | $0.91 | +9.1% |
| FY2016 | $0.83 | -17.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026